Hope Mackline

Dr. Hope Mackline


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2024 in Wellcome Open Research
Verified
Journal Article
Open access
HMHope Mackline
Hope Mackline
RKReuben Kiggundu
Reuben Kiggundu
DTDickson Tabajjwa
Dickson Tabajjwa
CTConrad Tumwine
Conrad Tumwine
FLFahad Lwigale
Fahad Lwigale
AKAndrew Kambugu
Andrew Kambugu
Introduction The World Health Organization global antimicrobial resistance surveillance system (GLASS) was rolled out in 2015 to guide antimicrobial resistance (AMR) surveillance. However, its implementation in Africa has not been fully evaluated. We conducted a scoping review to establish the progress of implementing the WHO 2015 GLASS manual in Africa. Methods We used MeSH terms to comprehensively search electronic databases (MEDLINE and Embase) for articles from Africa published in English between January 2016 and December 2023. The Arksey and O'Malley's methodological framework for scoping reviews was employed. Data were collected on compliance with WHO GLASS recommendations for AMR surveillance-priority samples, pathogens, and pathogen-antibiotic combinations and analysed using Microsoft Excel. Results Overall, 13,185 articles were identified. 7,409 were duplicates, and 5,141 articles were excluded based on titles and abstracts. 609 full-text articles were reviewed, and 147 were selected for data extraction. Of the 147 selected articles, 78.9% had been published between 2020 and 2023; 57.8% were from Eastern Africa. 93.9% of articles were on cross-sectional studies. 96.6% included only one priority sample type; blood (n=56), urine (n=64), and stool (n=22). Of the 60 articles that focused on blood as a priority sample type, 71.7%, 68.3%, 68.3%, 36.7%, 30%, and 10% reported recovery of Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Salmonella species and Streptococcus pneumoniae, respectively. Salmonella and Shigella species were reported to have been recovered from 91.3% and 73.9% of the 23 articles that focused on stool. E. coli and K. pneumoniae recoveries were also reported from 94.2% and 68.1% of the 69 articles that focused on urine. No article in this review reported having tested all the recommended WHO GLASS pathogen-antibiotic combinations for specific pathogens. Conclusion Progress has been made in implementing the GLASS recommendations in Africa, but adoption varies across countries limiting standardisation and comparability of data.

9 July 2025 in Wellcome Open Research
Verified
Journal Article
Open access
CTConrad Tumwine
Conrad Tumwine
RKReuben Kiggundu
Reuben Kiggundu
FLFahad Lwigale
Fahad Lwigale
HMHerman Mwanja
Herman Mwanja
HKHannington Katumba
Hannington Katumba
DBDathan Byonanebye
Dathan Byonanebye
Antimicrobial resistance (AMR) remains a critical global health challenge, and is mainly due to inappropriate antimicrobial use in human and animal health sectors. This systematic review examines the roles of Community Animal Health Workers (CAHWs) and Community Health Workers (CHWs) in antimicrobial stewardship (AMS) across Africa where AMR burden is highest and AMS programs are limited. Following PRISMA guidelines, this systematic review analyzed 16 studies (2017–2024) from nine African nations. We identified seven key roles of CAHWs and CHWs in AMS: 1) provision of clinical services (13 studies); 2) community mobilization (8 studies); 3) health promotion (7 studies); 4) provision of preventive services (5 studies); 5) epidemiological surveillance (4 studies); 6) advocacy (2 studies), and 7) medical waste management (2 studies). Despite their roles, challenges such as lack of supportive legislation (3 studies), inadequate remuneration (2 studies), and total reliance on foreign funding hinder AMS program sustainability. While most studies (14 studies) indicated that CAHWs and CHWs had received AMS training, their roles in the national AMR strategies remain unclear. CAHW and CHWs could be leveraged in advancing health promotion, raising AMR awareness, supporting AMR surveillance, enhancing integrated management of diseases, and improving waste management within One Health frameworks. To realize this potential, there is a need to formalize CAHW/CHW roles through targeted legislation, specialized training and sustainable funding. This evidence highlights the critical need for policy reforms to harness their potential in strengthening health systems and curbing AMR across Africa. PROSPERO registration number: CRD420251027215

8 November 2024 in JMIR Research Protocols
Verified
Journal Article
Open access
JMJonathan Mayito
Jonathan Mayito
CTConrad Tumwine
Conrad Tumwine
RGRonald Galiwango
Ronald Galiwango
ENElly Nuwamanya
Elly Nuwamanya
SNSuzan Nakasendwa
Suzan Nakasendwa
FKFrancis Kakooza
Francis Kakooza
Background: It is projected that drug-resistant infections will lead to 10 million deaths annually by 2050 if left unabated. Despite this threat, surveillance data from resource-limited settings are scarce and often lack antimicrobial resistance (AMR)–related clinical outcomes and economic burden. We aim to build an AMR and antimicrobial use (AMU) data warehouse, describe the trends of resistance and antibiotic use, determine the economic burden of AMR in Uganda, and develop a machine learning algorithm to predict AMR-related clinical outcomes. Objective: The overall objective of the study is to use data-driven approaches to optimize antibiotic use and combat antimicrobial-resistant infections in Uganda. We aim to (1) build a dynamic AMR and antimicrobial use and consumption (AMUC) data warehouse to support research in AMR and AMUC to inform AMR-related interventions and public health policy, (2) evaluate the trends in AMR and antibiotic use based on annual antibiotic and point prevalence survey data collected at 9 regional referral hospitals over a 5-year period, (3) develop a machine learning model to predict the clinical outcomes of patients with bacterial infectious syndromes due to drug-resistant pathogens, and (4) estimate the annual economic burden of AMR in Uganda using the cost-of-illness approach. Methods: We will conduct a study involving data curation, machine learning–based modeling, and cost-of-illness analysis using AMR and AMU data abstracted from procurement, human resources, and clinical records of patients with bacterial infectious syndromes at 9 regional referral hospitals in Uganda collected between 2018 and 2026. We will use data curation procedures, FLAIR (Findable, Linkable, Accessible, Interactable and Repeatable) principles, and role-based access control to build a robust and dynamic AMR and AMU data warehouse. We will also apply machine learning algorithms to model AMR-related clinical outcomes, advanced statistical analysis to study AMR and AMU trends, and cost-of-illness analysis to determine the AMR-related economic burden. Results: The study received funding from the Wellcome Trust through the Centers for Antimicrobial Optimisation Network (CAMO-Net) in April 2023. As of October 28, 2024, we completed data warehouse development, which is now under testing; completed data curation of the historical Fleming Fund surveillance data (2020-2023); and collected retrospective AMR records for 599 patients that contained clinical outcomes and cost-of-illness economic burden data across 9 surveillance sites for objectives 3 and 4, respectively. Conclusions: The data warehouse will promote access to rich and interlinked AMR and AMU data sets to answer AMR program and research questions using a wide evidence base. The AMR-related clinical outcomes model and cost data will facilitate improvement in the clinical management of AMR patients and guide resource allocation to support AMR surveillance and interventions. International Registered Report Identifier (IRRID): PRR1-10.2196/58116

15 November 2024 in JMIR Research Protocols
Verified
Journal Article
Open access
HMHope Mackline
Hope Mackline
RKReuben Kiggundu
Reuben Kiggundu
DBDathan Byonanebye
Dathan Byonanebye
JMJonathan Mayito
Jonathan Mayito
DTDickson Tabajjwa
Dickson Tabajjwa
FKFrancis Kakooza
Francis Kakooza
Background: Antimicrobial resistance (AMR) is a major global public health concern, particularly in low- and middle-income countries where resources and infrastructure for an adequate response are limited. The World Health Organization (WHO) Global Antimicrobial Resistance Surveillance System (GLASS) was introduced in 2016 to address these challenges, outlining recommendations for priority pathogen-antibiotic combinations. Despite this initiative, implementation in Africa remains understudied. This scoping review aims to assess the current state of implementing WHO GLASS recommendations on antimicrobial sensitivity testing (AST) in Africa. Objective: The primary objective of this study is to determine the current state of implementing the WHO GLASS recommendations on AST for priority pathogen-antimicrobial combinations. The review will further document if the reporting of AST results is according to “susceptible,” “intermediate,” and “resistant” recommendations according to GLASS. Methods: Following the methodological framework by Arksey and O’Malley, studies published between January 2016 and November 2023 will be included. Search strategies will target electronic databases, including MEDLINE, Scopus, CINAHL, and Embase. Eligible studies will document isolates tested for antimicrobial sensitivity, focusing on WHO-priority specimens and pathogens. Data extraction will focus on key study characteristics, study context, population, and adherence to WHO GLASS recommendations on AST. Descriptive statistics involving summarizing the quantitative data extracted through measures of central tendency and variation will be used. Covidence and Microsoft Excel software will be used. This study will systematically identify, collate, and analyze relevant studies and data sources based on clear inclusion criteria to provide a clear picture of the progress achieved in the implementation of the WHO GLASS recommendations. Areas for further improvement will be documented to inform future efforts to strengthen GLASS implementation for enhanced AMR surveillance in Africa. Results: The study results are expected in August 2024. Conclusions: To our knowledge, this scoping review will be the first to comprehensively examine the implementation of WHO GLASS recommendations in Africa, shedding light on the challenges and successes of AMR surveillance in the region. Addressing these issues aims to contribute to global efforts to combat AMR. International Registered Report Identifier (IRRID): PRR1-10.2196/58140

22 April 2025 in Wellcome Open Research
Verified
Journal Article
Open access
CSChristine Sekaggya-Wiltshire
Christine Sekaggya-Wiltshire
EOEva Agnes Laker Odongpiny
Eva Agnes Laker Odongpiny
FOFrancis Williams Ojara
Francis Williams Ojara
IKIsabella Kyohairwe
Isabella Kyohairwe
RKReuben Kiggundu
Reuben Kiggundu
AKAndrew Kambugu
Andrew Kambugu
Background Antimicrobial resistance (AMR) is a growing health concern, particularly in Africa, and is predicted to become the leading cause of death after cancer by 2050. Factors like overuse or inappropriate use of antibiotics contribute to this crisis. People living with HIV (PLWH) are particularly vulnerable to AMR with potential drug-drug interactions between antiretroviral and antimicrobial agents against common organisms like Mycobacterium tuberculosis. There is limited data on the concentrations of commonly used antimicrobial agents in people living with HIV in resource-limited settings. Therapeutic Drug Monitoring (TDM) offers a promising approach to optimize antibiotic dosing and improve treatment outcomes for those with sub-optimal drug concentrations. TDM has been recommended for PLWH on anti-tuberculosis treatment due to sub-optimal drug concentrations found in a significant proportion of those with TB. Objectives The main objectives of this study are to determine the concentrations of selected antimicrobial agents in people living with HIV requiring antimicrobial therapy and to assess the utility of therapeutic drug monitoring in achieving therapeutic targets for PLWH receiving rifampicin and isoniazid for the treatment of tuberculosis. Methods This prospective observational study will enroll adult PLWH receiving amoxicillin, azithromycin, ciprofloxacin, rifampicin, isoniazid, or ceftriaxone. Concentrations of these antibiotics will be measured locally using validated liquid chromatography mass spectrometry methods and high-performance liquid chromatography with ultraviolet detection. TDM with dose adjustment will be performed in a subset of participants on TB treatment. Pharmacokinetic parameters will be estimated using non-linear mixed effects models. Results This study was reviewed and approved by the research and ethics committee in February 2024. Participant enrolment began in September 2024. Conclusions We anticipate that the findings from this research will characterize pharmacokinetic and pharmacodynamics relationships to predict treatment response for optimal antimicrobial therapeutic and anti-tuberculosis dosing among people living with HIV (PLWH). Clinical registration The study is registered with Pan African Clinical Trials Registry, registration number PACTR202409710100607, registration date 07 August 2024, pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=31764

20 May 2026 in Wellcome Open Research
Verified
Journal Article
Open access
VTVivian Twemanye
Vivian Twemanye
CTConrad Tumwine
Conrad Tumwine
HMHerman Mwanja
Herman Mwanja
MSMorries Seru
Morries Seru
HAHarriet Akello
Harriet Akello
RKReuben Kiggundu
Reuben Kiggundu
Background Antimicrobial resistance (AMR) poses a significant challenge to global health, especially in low- and middle-income countries (LMICs). The World Health Organization (WHO) recommends point prevalence surveys (PPS) as a standardized method for monitoring antibiotic use in hospitals. This manuscript describes Uganda’s experience and lessons learned in implementing the World Health Organisation Point Prevalence Survey methodology (WPPS) in high-volume tertiary hospitals. Methods The WPPS methodology was adapted to align with the health system in Uganda, the existing policies, and information systems, prioritizing inpatient points of care with high antibiotic use, and involving multidisciplinary teams in data collection, capacity building, and continuous quality improvement initiatives. Digitization of the paper-based WPPS tool enhanced and streamlined data collection, reduced errors, and improved data accessibility. Conducting quarterly surveys based on similar methodologies, provided sufficient data points that allowed tracking of trends and gauged the effectiveness of AMS interventions over time, helping to overcome the limitations of single surveys or sparse snapshot data. Results Implementation of the WPPS was feasible and provided actionable outputs on antibiotic prescribing patterns. The approach facilitated capacity building, continuous quality improvement, and the ability to monitor trends in antimicrobial use over time. Key observations from implementation and routine feedback included inadequate documentation of prescriptions and their indications, limited digitalization of patient records, and challenges in integrating WPPS data with broader AMR surveillance systems. Conclusion Uganda’s experience suggests that the WPPS offers a feasible solution for gathering actionable data on antibiotic prescription patterns, which is essential for informing antimicrobial stewardship programmes and supporting policy decisions as intended. Leveraging these insights can strengthen surveillance in Uganda and could guide the development and implementation of AMR surveillance and monitoring frameworks in other LMICs. Strengthening integration with national AMR surveillance frameworks could further enhance the utility of these data in guiding interventions.